All In Biotech

Drug Trial Radar · NCT01962207

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

A PHASE IIIB, OPEN, MULTI-CENTER STUDY TO EVALUATE THE LONG-TERM ANTIBODY PERSISTENCE AT 6, 7, 8, 9 AND 10 YEARS AFTER THE ADMINISTRATION OF ONE DOSE OF THE MENINGOCOCCAL CONJUGATE VACCINE MENACWY-TT VERSUS ONE DOSE OF MENINGITEC(REGISTERED) VACCINE OR ONE DOSE OF THE MENINGOCOCCAL POLYSACCHARIDE VACCINE MENCEVAX(REGISTERED) ACWY, AND TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER PRIMARY VACCINATION OF 1-10 YEAR OLD SUBJECTS WITH MENACWY-TT, MENINGITEC(REGISTERED) OR MENCEVAX(REGISTERED) ACWY.

Last checked: Nov 19, 2026Latest source record: Jun 7, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

243

Actual

Start

Oct 2013

Primary completion

Dec 2017

Study completion Jun 2018

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 14, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term antibody persistence 6, 7, 8, 9 and 10 years after receiving a primary vaccination of meningococcal conjugate vaccine MenACWY-TT versus Meningitec™ or Mencevax™ ACWY, and the safety and immunogenicity of a booster dose of MenACWY-TT administered 10 years after the primary vaccination. All subjects received a primary vaccination at 1 to 10 years of age in study 108658 (NCT00427908). No new subjects will be enrolled in this booster study.

Conditions

  • Infections, Meningococcal

Interventions

  • Meningococcal vaccine GSK134612Biological

    One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary VaccinationTime frame: 6 years after primary vaccination (Year 1 of study MENACWY-TT-100)
  2. Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary VaccinationTime frame: 7 years after primary vaccination (Year 2 of study MENACWY-TT-100)
  3. Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary VaccinationTime frame: 8 years after primary vaccination (Year 3 of study MENACWY-TT-100)
  4. Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary VaccinationTime frame: 9 years after primary vaccination (Year 4 of study MENACWY-TT-100)
  5. Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary VaccinationTime frame: 10 years after primary vaccination (Year 4 of study MENACWY-TT-100)
  6. Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary VaccinationTime frame: 6 Years after primary vaccination (Year 1 of study MENACWY-TT-100)
  7. Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary VaccinationTime frame: 7 years after primary vaccination (Year 2 of study MENACWY-TT-100)
  8. Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary VaccinationTime frame: 8 years after primary vaccination (Year 3 of study MENACWY-TT-100)
  9. Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary VaccinationTime frame: 9 years after primary vaccination (Year 4 of study MENACWY-TT-100)
  10. Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary VaccinationTime frame: 10 years after primary vaccination (Year 5 of study MENACWY-TT-100)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Espoo Vaccine Research Clinic

    Espoo, Finland

  • South Helsinki Vaccine Research Clinic

    Helsinki, Finland

  • Helsinki East Vaccine Research Clinic

    Helsinki, Finland

  • Jarvenpaa Vaccine Research Clinic

    Jarvenpaa, Finland

  • Tampereen yliopisto/ Oulun rokotetutkimusklinikka

    Oulu, Finland

  • Tampereen yliopisto/ Porin rokotetutkimusklinikka

    Pori, Finland

  • Tampere Vaccine Research Clinic

    Tampere, Finland

  • Tampereen yliopisto/ Turun rokotetutkimusklinikka

    Turku, Finland

  • Tampereen yliopisto/ Ita-Vantaan rokotetutkimusklinikka

    Vantaa, Finland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.